Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection.

Article Details

Citation
Copy to clipboard

Waheed Y

Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection.

World J Virol. 2015 Feb 12;4(1):33-5. doi: 10.5501/wjv.v4.i1.33.

PubMed ID
25674516 [ View in PubMed
]
Abstract

Hepatitis C virus (HCV) has infected more than 200 million people around the globe. From 2001-2011, interferon plus ribavirin remained the standard of care for patients with HCV infection. The therapy had a limited response with a number of side effects. Recently, results for phase III trials of ledipasvir and sofosbuvir combination therapy have been announced. In treatment naive patients, 12 wk of therapy with ledipasvir and sofosbuvir showed a sustained virological response (SVR) rate of 99%. In treatment experienced patients, 12-24 wk of therapy with ledipasvir and sofosbuvir in the absence or presence of ribavirin showed an SVR rate of 94%-99%. In cirrhotic patients the rate of SVR was 86% and 99% for 12 and 24 wk of therapy, respectively. The ledipasvir and sofosbuvir therapy showed very good results in different subgroups of patients regardless of patient's race, alanine aminotransferase levels, sex and host genetic factors. The combination therapy was well tolerated with no emergence of resistant mutants. The most common adverse effects were nausea, headache and fatigue. With the availability of interferon free therapy with minimal adverse effects, it will be easy to decrease the future morbidity and mortality caused by HCV infection.

DrugBank Data that Cites this Article

Drugs